{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-384360","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2026-09-08T11:02:13+00:00","discovered_at":"2026-09-08T11:05:04.768145+00:00","generated_at":"2026-09-08T11:05:16.369430+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monte Rosa earns $50M milestone as Novartis starts Phase 2 Sjögren's study of MRT-6160","bullets":["Novartis initiated Phase 2a/b double-blind, placebo-controlled trial of VAV1 degrader MRT-6160 (DDY391) in Sjögren's disease; first patient visit triggers $50M payment to Monte Rosa.","Study tests up to 52 weeks of treatment; identifier NCT07737743; dose selection for Phase 3.","Monte Rosa eligible for up to $2.1B in development, regulatory, sales milestones from Novartis agreement.","Phase 1 data showed >90% VAV1 degradation in T cells with no serious adverse effects; additional Phase 2 studies expected.","Novartis funds Phase 2; Monte Rosa co-funds Phase 3 and shares 30% of U.S. profits/losses, plus ex-U.S. royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-384360","json":"https://secwatch.observer/filing/0001193125-26-384360.json","markdown":"https://secwatch.observer/filing/0001193125-26-384360.md","text":"https://secwatch.observer/filing/0001193125-26-384360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/0001193125-26-384360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:05:16.369430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}